Background KEYNOTE-181, ATTRACTION-3, and ESCORT trials have opened the era of
programmed death 1 (PD-1) inhibitors in the second-line therapy for esophageal squamous …

Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both
demonstrated significant overall survival (OS) benefit versus chemotherapy in previously …

Introduction The prognosis of advanced esophageal squamous cell carcinoma (ESCC) is
poor. Although cytotoxic drugs have been widely used in advanced ESCC, several antibody …

Background Programmed cell death 1 (PD-1)-based treatments are approved for several
cancers. CheckMate 648, a global, phase 3 trial, showed that first-line nivolumab (anti-PD-1 …

Importance Immune checkpoint inhibitors (ICIs) have improved survival outcomes of patients
with advanced esophageal squamous cell carcinoma in both first-and second-line settings …

Background First-line chemotherapy for advanced esophageal squamous-cell carcinoma
results in poor outcomes. The monoclonal antibody nivolumab has shown an overall …

290 Background: NIVO+ chemo and NIVO+ IPI demonstrated superior overall survival (OS)
vs chemo in CheckMate 648 (NCT03143153), leading to approvals in the US, EU, Japan …

Background Chemotherapy (CT) for advanced ESCC offers poor long-term survival. We
report the final analysis from the phase III ATTRACTION-3 study of the programmed death …

LBA4001 Background: NIVO demonstrated superior overall survival (OS) vs chemo in
previously treated patients (pts) with ESCC (ATTRACTION-3). We report OS and …

4035 Background: NIVO+ chemo and NIVO+ IPI demonstrated significant overall survival
(OS) benefit vs chemo in previously untreated patients (pts) with advanced ESCC in the …